^
HER-2 positive
GastroEsophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
PD-L1 overexpression
GastroEsophageal Cancer
PD1 inhibitor
Sensitive: B - Late Trials
PD-L1 overexpression
GastroEsophageal Cancer
PD-L1 inhibitor
Sensitive: B - Late Trials
PD-L1 expression
GastroEsophageal Cancer
pembrolizumab
Sensitive: C1 - Off-label
HER-2 positive
GastroEsophageal Cancer
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
GastroEsophageal Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
TP53 mutation
GastroEsophageal Cancer
Immunotherapy
Resistant: C3 – Early Trials
TET1 mutation
GastroEsophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 expression
GastroEsophageal Cancer
ZW25
Sensitive: C3 – Early Trials
PD-L1 expression
GastroEsophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 overexpression
GastroEsophageal Cancer
disitamab vedotin
Sensitive: C3 – Early Trials
PD-L1 expression
GastroEsophageal Cancer
tislelizumab
Sensitive: C3 – Early Trials
FGFR2 amplification
GastroEsophageal Cancer
ABSK-091
Sensitive: C3 – Early Trials
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive: C3 – Early Trials
TGFB1 elevation
GastroEsophageal Cancer
M7824
Sensitive: C3 – Early Trials
HER-2 overexpression
GastroEsophageal Cancer
ZW25
Sensitive: C3 – Early Trials
MET amplification
GastroEsophageal Cancer
afatinib
Resistant: C3 – Early Trials
EGFR amplification + ERBB2 amplification
GastroEsophageal Cancer
afatinib
Sensitive: C3 – Early Trials
CFB overexpression
GastroEsophageal Cancer
sunitinib
Sensitive: C3 – Early Trials
VEGFC-H
GastroEsophageal Cancer
sunitinib
Sensitive: C3 – Early Trials
HER-2 positive
GastroEsophageal Cancer
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
POLE mutation
GastroEsophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
POLD1 mutation
GastroEsophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
GastroEsophageal Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 expression
GastroEsophageal Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
HER-2 positive + HER-2 amplification
GastroEsophageal Cancer
trastuzumab
Sensitive: C3 – Early Trials
CTAG1A expression
GastroEsophageal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 mutation
GastroEsophageal Cancer
dasatinib
Sensitive: D – Preclinical
HER-2 mutation
GastroEsophageal Cancer
neratinib
Sensitive: D – Preclinical
HER-2 mutation
GastroEsophageal Cancer
dasatinib + neratinib
Sensitive: D – Preclinical
BCL2 overexpression + MCL1 overexpression
GastroEsophageal Cancer
AT 101
Sensitive: D – Preclinical